| Accession Number | 0000905148-26-001283 |
|---|---|
| Form Type | 4 |
| Filing Date | Mar 16, 2026 |
| Document | View SEC Filing |
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
President, Head of Global Oncology Research and Development | American Depositary Shares | โ | Mar 12, 2026 | Exercise/Conversion | 5,323 | โ | โ | 47,714 | Direct | โ | View Details | |
President, Head of Global Oncology Research and Development | American Depositary Shares | โ | Mar 13, 2026 | Sale | 2,957 | $18.63 | $55,083.00 | 44,757 | Direct | โ | View Details | |
President, Head of Global Oncology Research and Development | Stock Options (Right to Buy) | Derivative | Mar 4, 2026 | Grant/Award | 103,950 | $0.00 | $0.00 | 103,950 | Direct | โ | View Details | |
President, Head of Global Oncology Research and Development | Restricted Share Units | Derivative | Mar 4, 2026 | Grant/Award | 33,783 | $0.00 | $0.00 | 33,783 | Direct | โ | View Details | |
President, Head of Global Oncology Research and Development | Restricted Share Units | Derivative | Mar 12, 2026 | Exercise/Conversion | 5,323 | $0.00 | $0.00 | 15,971 | Direct | โ | View Details |